Evidence map›Paper›PMID 25241900›Full record

ArticleOncogene2015

Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.

E M Davies, A M Kong, A Tan, R Gurung, A Sriratana, P E Bukczynska, L M Ooms, C A McLean, T Tiganis, C A Mitchell

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. PI(4,5)PScience advances · 2023
    Article
  5. Article
  6. PTEN and Other PtdIns(3,4,5)PInternational journal of molecular sciences · 2020
    Review
  7. Review
  8. Article
  9. PI(3,4)PCancer science · 2017
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

E M DaviesDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
A M KongDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
A TanDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
R GurungDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
A SriratanaDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
P E BukczynskaDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
L M OomsDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
C A McLeanDepartment of Anatomical Pathology, Alfred Hospital, Prahran, Victoria, Australia.
T TiganisDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
C A MitchellDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Monash University · AUThe Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most common and lethal primary malignant brain tumor in adults. The tumor suppressor gene PTEN is deleted, mutated or hypermethylated in more than 60% of glioblastoma cases resulting in hyperactivation of the phosphoinositide 3-kinase pathway, which leads to sustained PI(3,4,5)P3 signaling, and thereby hyperactivation of Akt and other effectors. PI(3,4,5)P3 is also hydrolyzed to PI(3,4)P2 by inositol polyphosphate 5-phosphatases such as SKIP, but the role this pathway has in glioblastoma is unknown. Microarray expression profiling of SKIP in human glioblastoma has revealed both increased and decreased SKIP gene expression. Here we have screened PTEN-deficient glioblastoma for SKIP protein expression by immunohistochemistry and report that SKIP expression is increased in some cases or decreased relative to normal brain. Using the U-87MG PTEN-deficient cell line we show that SKIP knockdown did not further enhance cell proliferation or survival. However, SKIP overexpression in U-87MG cells suppressed anchorage-independent cell growth and growth factor-induced PI(3,4,5)P3/Akt signaling. Although, SKIP knockdown did not affect cell proliferation or survival, cell migration was significantly retarded, associated with significantly increased PI(4,5)P2 signals, and decreased phosphorylation of the actin-regulatory protein cofilin, a PI(4,5)P2-binding protein. Notably, overexpression of SKIP also inhibited migration of U-87MG cells to a similar degree as observed with PTEN reconstitution, however, via distinct mechanisms. PTEN reconstitution promoted sustained lamellipodia generation and focal adhesion formation. In contrast, SKIP overexpression reduced sustained lamellipodia formation, talin incorporation into focal adhesions and recruitment of PI(4,5)P2-binding proteins to the plasma membrane. Notably, analysis of two independent ONCOMINE microarray data sets revealed a significant correlation between increased SKIP mRNA expression in glioblastoma and improved long-term survival. Therefore, SKIP expression in glioblastoma may affect the local invasion of PTEN-deficient tumors.

Indexed as

Brain NeoplasmsCell Line, TumorCell MovementCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesGlioblastomaHumansMAP Kinase Signaling SystemOligonucleotide Array Sequence AnalysisPhosphoric Monoester HydrolasesPTEN PhosphohydrolaseSurvival AnalysisPhosphoric Monoester HydrolasesPTEN PhosphohydrolasePTEN protein, humanSKIP enzyme, human

Identifiers

PMID25241900
OpenAlexW2001498238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.